Proactive Investors - Run By Investors For Investors

AcelRx Pharmaceuticals shares soar following FDA advisory committee’s approval vote for Dsuvia

The Anesthetic and Analgesic Drug Products Advisory Committee voted 10-3 in favor of approving pain management drug Dsuvia
Two scientists sitting in a lab
The FDA’s final vote on Dsuvia will take place on November 3

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) shares are on the rise following an approval vote from the US Food and Drug Administration advisory committee on its opioid pain treatment drug.

The Anesthetic and Analgesic Drug Products Advisory Committee voted 10-3 in favor of approving Dsuvia for managing moderate-to-severe acute pain in medically supervised settings for adults.

Shares of the California-based pharmaceutical company jumped more than 20% to $4.85 in Monday pre-market trading.

READ: AcelRx Pharmaceuticals shares soar on expectation of positive FDA vote on opioid painkiller Dsuvia

The final vote will take place on November 3, taking into consideration the panel’s recommendation.

The FDA is proceeding with caution, given the rise in abuse of opioids in the US.

The regulatory agency rejected the new drug application for Dsuvia last year due to concerns about dosing and its usage directions.

Since then, AcelRx has lowered the drug’s maximum daily dose from 24 tablets to 12 tablets and provided new pooled safety analysis.

The drug’s directions were updated and a study was conducted to address concerns that the small size of the tablets would make them easy to misplace.

An analyst weighs in

Oppenheimer analyst Leland Gershell forecast that Dsuvia will be approved in November, citing the committee’s favorable vote.

However, Gershell highlighted some of the concerns brought forth by the advisory panel concerning efficacy and safety issues.

“AdComm discussion touched on several shortcomings, concerns. Among the points made, we highlight Dsuvia's dosing inflexibility, variable time to onset, lack of data in elderly patients, and absence of active comparator data,” stated Gershell.

The analyst reiterated an Outperform rating for AcelRx.


Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee

View full ACRX profile View Profile

AcelRx Pharmaceuticals Timeline

Related Articles

December 17 2018
Summit has big plans for its flagship ridinilazole C. Diff treatment as well as its gonorrhoea and hospital superbug candidates this year, and it now has the funds to develop all of them as intended
November 29 2018
The deal with New England Biolabs, signed in October, is expected to secure six-figure royalty sums as soon as next year
August 22 2018
The group's products are extracted from flaxseeds, a plentiful and non-animal source of omega-3.
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use